In February 2013, following the successful estab-lishment of the National Human Papillomavirus (HPV) Vaccination Program for females in Australia in 2007,1,2 the program was extended to males. This followed a recommendation by the Pharmaceutical Benefits Advisory Committee that extension of the quadrivalent HPV vaccine pro-gram to males would be acceptably cost-effective compared with female only vaccination,3 and subsequent listing on the National Immunisation Program of quadrivalent HPV vaccine for males. The program extends routine school-based HPV vaccination offered during the first year of high school (at age approx 12–13 years) to males, with a 2 year catch-up program for males aged 14–15years delivered in 2013 and 2014. The 3dose coverage (completed course) in the female program has been consistently around 71% by age 15years, with higher 1 (~81%) and 2 (~79%) dose coverage (National HPV Vaccination Program coverage data (http://www.hpvregister.org.au/research/coverage-data)). In this report we present interim estimates of male HPV vaccination cover-age achieved in the school-based program in 2013.